Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Ingrid Mayer on Targeted Therapies in ER+ Breast Cancer

February 3rd 2016

Ingrid A. Mayer, MD, co-leader and Clinical Director, Breast Cancer Research Program Chair, Data and Safety Monitoring Committee, Associate Professor of Medicine (Hematology/Oncology), medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the use of targeted therapies in estrogen-receptor (ER)-positive breast cancer.

Prospects in the Management of Breast Cancer

February 2nd 2016

Immunotherapy in Breast Cancer

February 2nd 2016

Analyzing the Use of Eribulin in Metastatic Breast Cancer

February 2nd 2016

Neoadjuvant Treatment in Triple-Negative Breast Cancer

February 2nd 2016

Post-Adjuvant Breast Cancer Treatment

February 2nd 2016

Neoadjuvant Therapy for HER2+ Breast Cancer

February 2nd 2016

MARIANNE and BOLERO-1 Trial Results in Breast Cancer

February 2nd 2016

First-Line Treatment of HER2-Positive MBC

February 2nd 2016

Managing Mouth Sores in Patients with Breast Cancer

February 2nd 2016

Review of Clinical Data on Palbociclib in Breast Cancer

February 2nd 2016

The Role of Fulvestrant in Metastatic HR+ Breast Cancer

February 2nd 2016

Appropriate Duration of Endocrine Therapy in Breast Cancer

February 2nd 2016

Managing Luminal A and Luminal B Breast Cancer

February 2nd 2016

Genomic Testing in Breast Cancer

February 2nd 2016

Treating Intermediate Risk Individuals with Breast Cancer

February 2nd 2016

Borgen Blasts USPSTF Breast Cancer Screening Guidelines

February 1st 2016

Patrick I. Borgen, MD, explains his strong opposition to the USPSTF guidelines and view that annual mammograms must remain a standard in clinical practice.

Breast Cancer Chemoprevention: Targeting the Estrogen Receptor

January 31st 2016

New strategies to increase the uptake of these proven breast cancer risk-reduction interventions in general clinical practice are needed.

Olaparib Studies Put Focus on BRCA-Positive Breast Cancers

January 30th 2016

The identification of the BRCA1 and BRCA2 tumor suppressor genes and the recognition that inherited loss of function (deleterious) mutations in one of these important genes places women at high risk for the development of breast, ovarian, and other cancers are major advances in womenâ€™s health research.

Dr. Aditya Bardia on RAD1901 in ER-Positive Metastatic Breast Cancer

January 29th 2016

Aditya Bardia, MD, MPH, assistant professor of Medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses RAD1901, a selective estrogen receptor degrader (SERD) for potential use in ER-positive metastatic breast cancer.